We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
447 hedge funds and large institutions have $10.1B invested in Royalty Pharma in 2025 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 160 increasing their positions, 149 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
160% more call options, than puts
Call options by funds: $89M | Put options by funds: $34.2M
68% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 50
22% more capital invested
Capital invested by funds: $8.21B → $10.1B (+$1.84B)
7% more funds holding
Funds holding: 416 → 447 (+31)
2.07% more ownership
Funds ownership: 72.43% → 74.49% (+2.1%)
7% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 149
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Holders
447
Holders Change
+31
Holders Change %
+7.45%
% of All Funds
5.99%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.09%
New
84
Increased
160
Reduced
149
Closed
50
Calls
$89M
Puts
$34.2M
Net Calls
+$54.8M
Net Calls Change
+$39.9M
Top Buyers
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$340M |
| 2 |
Millennium Management
New York
|
-$66.8M |
| 3 |
SGA
Siguler Guff Advisers
New York
|
-$60.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$56.3M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$52.1M |
